产品说明书

BO-264

Print
Chemical Structure| 2408648-20-2 同义名 : -
CAS号 : 2408648-20-2
货号 : A1262988
分子式 : C18H19N5O3
纯度 : 99%+
分子量 : 353.375
MDL号 : MFCD32671323
存储条件:

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(141.49 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
靶点
  • FGFR3

描述 TACC3 (transforming acidic coiled-coil 3), a transforming acidic coiled-coil (TACC) family member, is frequently upregulated in a broad spectrum of cancers, including breast cancer. It plays critical roles in protecting microtubule stability and centrosome integrity that is often dysregulated in cancers. BO-264 is a potential TACC3 inhibitor having an IC50 of 188 nM. Treatment of JIMT-1 cells with 1 μM BO-264 for 6 hours has led to a considerable stabilization of the cellular TACC3 upon increased temperatures. BO-264 inhibited the viability of basal (MDA-MB-231, MDA-MB-436, CAL51, and HCC1143) and HER2+ (JIMT-1 and HCC1954) breast cancer cell lines at lower doses compared with luminal A (MCF-7, T-47D, and ZR-75-1) and luminal B (BT-474) breast cancer cell lines. Similarly, a significantly lower average colony number of JIMT-1 cells was seen upon treatment with BO-264 for 12 days. Despite a relatively lower sensitivity to TACC3 inhibition in RT4 cells, BO-264 yielded the lowest IC50 value in both models (two human urinary bladder cancer cell lines, RT112 and RT4) as compared with SPL-B and KHS101 (other TACC3 inhibitors), suggesting BO-264 might be a highly relevant therapeutic opportunity to target FGFR3–TACC3 fusion-harboring tumors. Moreover, BO-264 decreased ERK1/2 phosphorylation, which is a marker for activated FGFR signaling along with a strong mitotic arrest at minimum 10× lower doses than other TACC3 inhibitors, suggesting that BO-264 specifically blocks the function of FGFR3–TACC3 fusion protein. BO-264 exhibited a remarkable anticancer activity against more than 90% of the cell lines representing nine different subpanels with GI50 values less than 1 μM. siTACC3-induced mitotic arrest, apoptosis, and DNA damage were fully recapitulated by BO-264 in a dose-dependent manner. Furthermore, treatment of JIMT-1 cells with BO-264 for 48 hours induced a prominent increase (from 4.1% to 45.6%) in the fraction of apoptotic cells[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.83mL

0.57mL

0.28mL

14.15mL

2.83mL

1.41mL

28.30mL

5.66mL

2.83mL

参考文献

[1]Akbulut O, Lengerli D, Saatci O, et al. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate. Mol Cancer Ther. 2020;19(6):1243-1254